Saturday 17 October 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
19.81
1.53
−7.17%
Follow FLGT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 2 | 4 | 7 |
+8 more TTM periods Free account |
| (8.01%) | (6.81%) | (5.41%) | (3.81%) | ||
| (7.37%) | (6.25%) | (4.97%) | (3.51%) | ||
ROIC |
(10.34%) | (8.62%) | (7.39%) | (5.96%) | |
Return on Tangible Assets |
(17.01%) | (14.61%) | (10.47%) | (7.86%) | |
Average Days of Receivables |
73.17 | 78.93 | 95.88 | 82.34 | |
Free Cash Flow per Share |
(3.71) | (3.66) | (4.04) | (0.65) | |
Free Cash Flow |
(103.78) | (113.16) | (124.21) | (19.84) | |
Capital Expenditures |
(20.08) | (23.05) | (22.57) | (21.37) | |
| Other line items | |||||
Cash ROIC |
(8.28%) | (8.57%) | (8.61%) | (1.33%) | |
Accounts Receivable Turnover |
4.56 | 4.55 | 4.20 | 4.91 | |
Accounts Payable Turnover |
12.12 | 9.98 | 10.36 | 9.79 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
27.21 | 39.27 | 35.50 | 35.61 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.08) | (0.11) | (0.12) | (0.09) | |
Research and Development Expense of Revenue |
17.52% | 17.38% | 16.71% | 16.43% | |
Selling, General and Administrative Expense of Revenue |
52.46% | 51.88% | 49.60% | 44.78% | |
Share Based Compensation of Revenue |
11.58% | 12.15% | 12.27% | 12.90% | |
Interest Coverage |
(1,019.02) | (1,357.99) | (1,214.61) | (717.10) | |
Operating CF/Net income |
0.99 | 1.22 | 1.68 | (0.04) | |
Depreciation/Fixed assets |
0.20 | 0.17 | 0.17 | 0.16 | |
Capex/Depreciation |
(0.91) | (1.16) | (1.19) | (1.16) | |
Revenue per Share |
11.57 | 10.37 | 10.48 | 10.26 | |
Operating CF per Share |
(2.99) | (2.92) | (3.30) | 0.05 | |
Capex per Share |
(0.72) | (0.75) | (0.73) | (0.69) | |
Capex to Sales |
0.06 | 0.07 | 0.07 | 0.07 |
Columns are period end dates